ARDT
Ardent Health Partners, LLC
ARDT has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over ARDT overall, supported by stronger fundamentals and stronger valuation.
ARDT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
ARDT's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ARDT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.5x | $6.75 | -62% |
| Fair | 9x | $9.25 | -48% |
| Forward | 15x | $17.68 | — |
| Current | 17x | $17.68 | — |
| Expensive | 20x | $20.97 | +19% |
Historical ranges are pointers, not guarantees.
ARDT's PE is in its expensive range at 17x. If earnings grow as analysts expect, today's price would be 15x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ARDT in the historical PE scenario, which offers more potential upside but is not a forecast.
ARDT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect ARDT's earnings to grow and its profitability to improve, with its revenue holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over ARDT on the outlook, with more favorable revenue expectations.
ARDT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.21 | +17% |
| Q3 2026 | $1.03 | -30% |
| Q2 2026 | $0.55 | -70% |
| Q1 2026 | $0.95 | -42% |
| Q4 2025 | $0.96 | -38% |
| Q3 2025 | $1.47 | +119% |
| Q2 2025 | $1.83 | +190% |
| Q1 2025 | $1.65 | +217% |
| Q4 2024 | $1.55 | +343% |
ARDT's earnings per share have fallen from their peak: $1.03 over the past year, against $1.83 in mid-2025.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ARDT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6B | +3.1% |
| Q2 2026 | $1.6B | -1.4% |
| Q1 2026 | $1.6B | +7% |
| Q4 2025 | $1.6B | -0.1% |
| Q3 2025 | $1.6B | +8.8% |
| Q2 2025 | $1.6B | +12% |
| Q1 2025 | $1.5B | +4% |
| Q4 2024 | $1.6B | +19% |
ARDT's revenue grew through 2024 and has held roughly level since: $1.6B last quarter, up 3.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5% | +5.1 points |
| Q2 2026 | 2.7% | -4.8 points |
| Q1 2026 | 4.7% | -0.3 points |
| Q4 2025 | 5.8% | -4.7 points |
| Q3 2025 | -0.1% | -4.1 points |
| Q2 2025 | 7.4% | +1.8 points |
| Q1 2025 | 5% | -0.3 points |
| Q4 2024 | 10% | -2.4 points |
ARDT has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ARDT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ARDT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $121.9M | -21% |
| Q2 2026 | $196.7M | +67% |
| Q1 2026 | -$60.2M | -$35.4M |
| Q4 2025 | $223.4M | +87% |
| Q3 2025 | $154.4M | +72% |
| Q1 2025 | -$24.8M | +$13.7M |
| Q4 2024 | $119.6M | +1090% |
| Q3 2024 | $89.7M | +41% |
ARDT generated $482M in free cash flow over the past year, up 31% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ARDT on cash flow, with more consistent year-over-year improvement.
ARDT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.9% | -1.3M shares |
| 1 year | +0.3% | +478K shares |
| 3 years | +0.5% | +741K shares |
| 5 years | +86% | +65.7M shares |
ARDT has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $11M |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2018 | — |
| Q3 2018 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ARDT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 1.0x | Healthy |
| Q1 2026 | 1.1x | Healthy |
| Q4 2025 | 0.9x | Very low |
| Q3 2025 | 1.0x | Very low |
| Q2 2025 | 1.0x | Healthy |
| Q1 2024 | 5.1x | High |
| Q4 2023 | 5.5x | High |
ARDT's net debt is less than a year of its operating earnings (EBITDA).
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ARDT on leverage, with a lower net debt burden relative to earnings.
ARDT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 82.1 | Overbought |
| Stochastic | 88.7 | Overbought |
ARDT's weekly RSI is 82 (overbought) and its Stochastic is 89 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ARDT PE vs Healthcare Sector
| Metric | ARDT | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 26x | 34% below |
| PE % | 75 | 54 | 21 pts above |
ARDT is trading at 17x earnings, a 34% discount to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ARDT on valuation relative to its sector.
ARDT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.9 | 37% above |
| 20 week MA | $11.6 | 52% above |
| 50 week MA | $10.1 | 74% above |
| 100 week MA | $11.8 | 50% above |
OSCR has stronger trend alignment. ARDT is above 4 of 4 weekly averages versus OSCR above 5 of 5.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
ARDT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $17.3 | $16.9 | -2.3% |
| 2025 | $16.9 | $9.22 | -45% |
| 2026 YTD | $9.22 | $17.7 | +92% |
ARDT has finished every year since 2024 lower, and it's up 92% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ARDT on returns for 2026, with the stronger performance.